TABLE 2.

Long-Term Study—Mean Changes From Baseline in Prolactin (ng/mL) by Sex, Baseline Prolactin Status, and Prior Treatment

	Baseline Status	Low				Normal				>1× ULN
	Treatment	Prior placebo	Prior brexpiprazole	Prior ADT	Prior quetiapine	Prior placebo	Prior brexpiprazole	Prior ADT	Prior quetiapine	Prior placebo	Prior brexpiprazole	Prior ADT	Prior quetiapine
Females
	Baseline
	Mean	2.33	—	2.15	—	9.40	13.81	9.87	9.03	40.32	39.63	42.43	39.16
	(SD)	(0.19)		(0.75)		(4.62)	(5.97)	(4.82)	(4.16)	(28.76)	(21.00)	(22.94)	(19.94)
	[Median]	[2.28]		[2.45]		[8.56]	[13.62]	[8.59]	[8.49]	[29.96]	[34.20]	[32.43]	[30.23]
	n	3		14		345	421	1040	45	15	53	34	4
	Change week 26;
	Mean	5.23	—	3.81	—	5.94	0.64	3.63	3.27	−8.72	−14.81	−18.29	−25.22
	(SD)	(0)		(2.68)		(9.92)	(15.11)	(7.86)	(6.45)	(33.02)	(28.39)	(28.30)	(23.93)
	[Median]	[5.23]		[3.54]		[4.99]	[−0.98]	[2.30]	[2.54]	[−4.73]	[−12.73]	[−13.62]	[−16.80]
	n	1		10		225	284	754	34	10	33	26	4
	Change week 52;
	Mean	—	—	2.29	—	4.08	−2.20	3.01	1.66	−13.56	−12.57	−8.18	—
	(SD)			(0)		(7.22)	(7.00)	(6.05)	(0)	(2.50)	(12.41)	(21.21)
	[Median]			[2.29]		[2.70]	[−2.41]	[2.20]	[1.66]	[−14.28]	[−12.20]	[−9.84]
	n			1		113	180	184	1	4	22	6
Males
	Baseline
	Mean	1.62	1.96	1.85	—	6.88	8.04	7.07	6.64	20.54	17.67	23.05	30.31
	(SD)	(0.96)	(0.75)	(0.92)		(2.63)	(2.38)	(2.46)	(2.01)	(8.91)	(4.91)	(13.61)	(21.39)
	[Median]	[2.01]	[1.96]	[2.26]		[6.54]	[8.19]	[6.69]	[6.14]	[18.21]	[15.85]	[16.99]	[30.31]
	n	5	2	10		125	185	457	23	17	37	66	2
	Change week 26;
	Mean	5.57	5.50	2.53	—	2.24	0.66	2.11	6.87	−7.14	−1.80	−4.44	—
	(SD)	(7.01)	(0)	(1.55)		(3.39)	(5.05)	(5.08)	(10.06)	(13.16)	(9.10)	(13.98)
	[Median]	[3.34]	[5.50]	[2.69]		[1.89]	[−0.21]	[1.37]	[2.32]	[−4.80]	[−2.75]	[−3.05]
	n	4	1	7		86	118	337	13	13	24	53
	Change week 52;
	Mean	1.48	—	2.81	—	2.97	0.35	1.07	—	−5.78	−5.01	−1.63	—
	(SD)	(0.73)		(2.88)		(5.62)	(4.03)	(3.32)		(4.08)	(5.36)	(17.27)
	[Median]	[1.48]		[2.81]		[1.41]	[−0.40]	[0.89]		[−6.43]	[−4.07]	[−3.09]
	n	2		2		46	71	74		8	20	16